Biopharmaceutical company Bioxytran, Inc. recently announced positive progress in the dose optimization study of its investigational drug Prolectin-M.

This key breakthrough has laid an important foundation for advancing the phase III registration clinical trial of this drug. Research data show that through systematic dose exploration, Prolectin-M has achieved an ideal balance between efficacy and safety. This result not only validates previous clinical data but also provides a scientific basis for the design of subsequent large-scale trials. The company plans to accelerate preparations for the phase III clinical trial based on the existing data. If the follow-up trials progress smoothly, Prolectin-M is expected to become an important treatment option for relevant indications.